Baseline characteristics in 1638 patients with polycythemia vera recruited in the ECLAP Project.
| Demographics . | n . |
|---|---|
| * For continuous variables, values are mean ± SD. | |
| Age at recruitment (years) | 65.4 (12.7)* |
| Males | 942 (57.5) |
| Body mass index, kg/m2 | 25.4 (3.7)* |
| Age at diagnosis (years) | 60.4 (13.2) |
| Years from diagnosis to enrollment | |
| 0–2 | 581 (35.5) |
| 3–5 | 434 (26.5) |
| 6–10 | 387 (23.6) |
| > 10 | 236 (14.4) |
| Prior cardiovascular events | |
| Prior thrombosis | 633 (38.6) |
| Prior arterial thrombosis | 470 (28.7) |
| AMI | 146 (8.9) |
| Stroke | 145 (8.9) |
| Transient ischemic attack | 169 (10.3) |
| Peripheral | 90 (5.5) |
| Prior venous thrombosis | 225 (13.7) |
| Deep vein thrombosis | 134 (8.4) |
| Pulmonary embolism | 39 (2.4) |
| Superficial thrombophlebitis | 100 (6.1) |
| Erythromelalgia | 86 (5.3) |
| Intermittent claudication | 77 (4.7) |
| Prior bleeding | 133 (8.1) |
| Packed cell volume (l/l) | 0.47 (0.06)* |
| Packed cell volume (l/l) | |
| ≤ 0.45 | 556 (38.9) |
| 0.46–0.50 | 530 (37.0) |
| > 0.50 | 345 (24.1) |
| Platelet count (×109/L) | 398 (208)* |
| White blood cell count (×109/L) | 10.9 (8.6)* |
| Antiplatelet drugs | 955 (58.3) |
| Cytoreductive treatments | |
| Phlebotomy | 1040 (63.5) |
| Any cytoreductive drug | 1009 (61.6) |
| Hydroxyurea | 793 (48.4) |
| Pipobroman | 106 (6.5) |
| Interferon | 64 (3.9) |
| Busulfan | 61 (3.7) |
| 32P | 44 (2.7) |
| Chlorambucil | 5 (0.3) |
| Demographics . | n . |
|---|---|
| * For continuous variables, values are mean ± SD. | |
| Age at recruitment (years) | 65.4 (12.7)* |
| Males | 942 (57.5) |
| Body mass index, kg/m2 | 25.4 (3.7)* |
| Age at diagnosis (years) | 60.4 (13.2) |
| Years from diagnosis to enrollment | |
| 0–2 | 581 (35.5) |
| 3–5 | 434 (26.5) |
| 6–10 | 387 (23.6) |
| > 10 | 236 (14.4) |
| Prior cardiovascular events | |
| Prior thrombosis | 633 (38.6) |
| Prior arterial thrombosis | 470 (28.7) |
| AMI | 146 (8.9) |
| Stroke | 145 (8.9) |
| Transient ischemic attack | 169 (10.3) |
| Peripheral | 90 (5.5) |
| Prior venous thrombosis | 225 (13.7) |
| Deep vein thrombosis | 134 (8.4) |
| Pulmonary embolism | 39 (2.4) |
| Superficial thrombophlebitis | 100 (6.1) |
| Erythromelalgia | 86 (5.3) |
| Intermittent claudication | 77 (4.7) |
| Prior bleeding | 133 (8.1) |
| Packed cell volume (l/l) | 0.47 (0.06)* |
| Packed cell volume (l/l) | |
| ≤ 0.45 | 556 (38.9) |
| 0.46–0.50 | 530 (37.0) |
| > 0.50 | 345 (24.1) |
| Platelet count (×109/L) | 398 (208)* |
| White blood cell count (×109/L) | 10.9 (8.6)* |
| Antiplatelet drugs | 955 (58.3) |
| Cytoreductive treatments | |
| Phlebotomy | 1040 (63.5) |
| Any cytoreductive drug | 1009 (61.6) |
| Hydroxyurea | 793 (48.4) |
| Pipobroman | 106 (6.5) |
| Interferon | 64 (3.9) |
| Busulfan | 61 (3.7) |
| 32P | 44 (2.7) |
| Chlorambucil | 5 (0.3) |